At the molecular level, the levels of mTORC2 target phosphorylated/activated p-AKTS473, the mTORC1 target phosphorylated/activated p-RPS6 as well as phosphorylated/activated p-mTOR were strikingly reduced following MLN0128 administration in all HCC cell lines tested, whereas inconsistent results were detected when assessing the levels of phosphorylated PI3K (Figure 4). The gene discussed is RPS6; the disease is hepatocellular carcinoma.